Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P683 Infliximab, adalimumab and vedolizumab levels are not altered by pregnancy progression in IBD patients and neonatal vedolizumab levels are lower than in mothers: Results from the PICCOLO study

ECCO'20 Vienna

Year: 2020
Authors:

E. Flanagan1, P.R. GIbson2, O. Rosella3, A. Ross4, S.J. Bell4, The PICCOLO Study

1Department of Gastroenterology, St Vincent’s Hospital Melbourne, Fitzroy, Australia, 2Department of Gastroenterology, Alfred Health, Monash, Australia, 3Department of Gastroenterology, Monash University, Melbourne, Australia, 4Department of Gastroenterology, St Vincent’s Hospital Melbourne, Melbourne, Australia

P684 The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: updated results from the tofacitinib ulcerative colitis clinical programme

ECCO'20 Vienna

Year: 2020
Authors:

B.E. Sands1, P.R. Taub2, B.G. Feagan3, A. Armuzzi4, A.O. Damião5, N. Lawendy6, G. Solano7, K. Kwok8, J. Woolcott6, L. Salese6, C. Su6

1Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York- NY, USA, 2Division of Cardiovascular Medicine- UC San Diego School of Medicine, La Jolla, California, USA, 3Robarts Clinical Trials- Western University, London, Ontario, Canada, 4IBD Unit- Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, 5Department of Gastroenterology, University of São Paulo USP, São Paulo, Brazil, 6Pfizer Inc., Collegeville, Pennsylvania, USA, 7Pfizer Inc., San José, Costa Rica, Costa Rica, 8Pfizer Inc., New York, New York, USA

P685 Healthcare resource use associated with ferric maltol and IV iron treatment for iron deficiency anaemia in patients with inflammatory bowel diseaseECCO'20 Vienna
Year: 2020
Authors: S. Howaldt1, I. Jacob2, M. Sampson3, F. Akriche4

1MZV für Immunologie, Gastroenterology, Hamburg, Germany, 2Health Economics and Outcomes Research Ltd., Health economics, Cardiff, UK, 3Shield Therapeutics PLC, Medical, London, UK, 4Norgine Ltd., Medical, Rueil Malmaison, France

Corrigendum:

In the originally published version of this poster presentation, the below corrections have been made.

Upon the original publication, the following sentence in Results section should read: “The primary endpoint was not met.” instead of “The non-inferiority endpoint was met.”.

Upon the original publication, the final concluding remarks should read: “FM is associated with substantially lower HCRU than IV FCM, and may provide a cost-effective oral alternative to IV iron in patients with IBD.” instead of “FM is associated with non-inferior efficacy and substantially lower HCRU than IV FCM, and may provide a cost-effective oral alternative to IV iron in patients with IBD.”.

P686 Expression of CD39 ectonucleotidase on regulatory T cells and on T helper 17 cells in children with IBD receiving anti-TNF therapy

ECCO'20 Vienna

Year: 2020
Authors:

S.V. Petrichuk1, Т. Radygina1, A. Illarionov2, D. Kuptsova1, A. Potapov3, A.P. Fisenko3

1National Medical Research Center for Children’s Health, Laboratory of Experimental Immunology and Virology, Moscow, Russian Federation, 2Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Department of Pediatrics and Rheumatology, Moscow, Russian Federation, 3National Medical Research Center for Children’s Health, Gastroenterology and Hepatology, Moscow, Russian Federation

P687 Early and sustained improvement in stool frequency and rectal bleeding following 52 weeks of mirikizumab treatment

ECCO'20 Vienna

Year: 2020
Authors:

G.R. D’Haens1, T. Hibi2, M. Ferrante3, B.R. Bhandari4, E. Berliba5, J.L. Tuttle6, T. Lissoos7, K. Krueger7, N. Morris7, V. Arora7, A.N. Naegeli7, B.G. Feagan8

1Amsterdam University Medical Centers, Inflammatory Bowel Disease Centre, Amsterdam, The Netherlands, 2Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan, 3Universitair Ziekenhuizen Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 4Delta Research Partners, n/a, Bastrop, LA, USA, 5Nicolae Testemitanu State University of Medicine, Arsenia Exploratory Medicine, Chisinau, Moldova Republic of, 6Eli Lilly and Company, Lilly Biotechnology Center, San Diego, CA, USA, 7Eli Lilly and Company, Lilly Biomedicines, Indianapolis, IN, USA, 8Western University, Robarts Clinical Trials Inc., London, ON, Canada

P688 Effect of golimumab induction therapy on histologic disease profile in patients with moderate to severe ulcerative colitis: Results from the randomised, placebo-controlled Phase 3 PURSUIT-SC trial

ECCO'20 Vienna

Year: 2020
Authors:

T. Johansson1, C. Weinstein2, A. MEEHAN3, A. Tzontcheva4, P. Xu4, C. Marano5, G. de Hertogh6

1MSD, Medical Affairs, Kriens, Switzerland, 2Merck and Co. Inc., Clinical Research, Kenilworth, USA, 3Merck and Co. Inc., Global Scientific and Medical Publications, Kenilworth, USA, 4Merck and Co. Inc., Biostatistics, Kenilworth, USA, 5Janssen Research and Development, LLC, Clinical Research, Spring House, USA, 6University Hospitals KU Leuven, Pathology, Leuven, Belgium

P689 Patient-reported outcomes (PRO-2) and intestinal ultrasound in ulcerative colitis patients: subanalysis of the TRUST&UC study cohort

ECCO'20 Vienna

Year: 2020
Authors:

C. Maaser1, U. Helwig2, I. Fischer3, S. Rath4, S. Kolterer4, T. Kucharzik5

1Hospital Lüneburg, Outpatients Department of Gastroenterology, Lüneburg, Germany, 2Gastroenterology Practice, n.a., Oldenburg, Germany, 3Biostatistik Tuebingen, n.a., Tuebingen, Germany, 4AbbVie Deutschland GmbH & Co. KG, Medical Department, Wiesbaden, Germany, 5University Teaching Hospital Lueneburg, Department of Internal Medicine and Gastroenterology, Lueneburg, Germany

P690 A propensity score weighted comparison of vedolizumab, adalimumab, and golimumab in patients with ulcerative colitis: Real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

ECCO'20 Vienna

Year: 2020
Authors:

F.S. Macaluso1, M. Ventimiglia1, W. Fries2, A. Viola2, M. Cappello3, B. Scrivo3, A. Magnano4, D. Pluchino4, S. Camilleri5, S. Garufi5, R. Di Mitri6, F. Mocciaro6, G. Magrì7, C. Ferracane7, M. Citrano8, F. Graziano8, C. Bertolami9, S. Renna1, R. Orlando1, G. Rizzuto1, M. Cottone1, A. Orlando1, Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

1A.O.O.R. ‘Villa Sofia-Cervello’, IBD Unit, Department of Medicine, Palermo, Italy, 2A.O.U. Policlinico ‘G. Martino’, Inflammatory bowel disease Unit, Messina, Italy, 3A.O.U. Policlinico ‘G. Giaccone’, Gastroenterology and Hepatology Unit, Palermo, Italy, 4A.O.U. Policlinico ‘Vittorio Emanuele’, Gastroenterology Unit, Catania, Italy, 5A.O.O.R. ‘S. Elia- M. Raimondi’, Gastroenterology Unit, Caltanissetta, Italy, 6A.R.N.A.S. ‘Civico Di Cristina Benfratelli’, Gastroenterology and endoscopy Unit, Palermo, Italy, 7A.O. ‘Santa Marta e S. Venera’, Gastroenterology Unit, Acireale, Italy, 8A.O.O.R. ‘Villa Sofia-Cervello’, Pediatrics Unit, Palermo, Italy, 9A.O.O.R. ‘Papardo Piemonte’, Gastroenterology Unit-, Messina, Italy

P691 Corticosteroids usage in patients with inflammatory bowel disease: Results of a multi-national audit in Asia

ECCO'20 Vienna

Year: 2020
Authors:

D.H. Kim1, D.I. Park2, T. Kobayashi3, V. Ahuja4, B.I. Jang5, Q. Cao6, Y.J. Lee7, Z. Ran8, Clinical Research Committee of Asian Organization for Crohn’s and Colitis (AOCC)

1Cha Bundang Medical Center, Cha University School of Medicine, Digestive Disease Center, Seongnam, Korea Republic of, 2Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea Republic of, 3Center for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Kitasato University, Tokyo, Japan, 4Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India, 5Division of Gastroenterology and Hepatology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea Republic of, 6Department of Inflammatory Bowel Disease Center, Sir Run Run Shaw Hospital, Hangzhou, China, 7Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea Republic of, 8Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

P692 Exploring relationships between microbiome, faecal calprotectin and healthy eating index in patients with ulcerative colitis: Interim analyses of a randomised controlled trial

ECCO'20 Vienna

Year: 2020
Authors:

M. Raman1, L. Taylor1, A. Schick2, C. Ohland2, K. McCoy2, S. Kaur1, R. Panaccione1, R. Reimer3

1Department of Medicine, University of Calgary, Calgary, Canada, 2University of Calgary, Snyder, Calgary, Canada, 3Department of Kinesiology, University of Calgary, Calgary, Canada

P693 Development and evaluation of i-TRACKER infliximab and i-TRACKER anti-Infliximab kits: fast and innovative chemiluminescent assays for the monitoring of patients treated with infliximab

ECCO'20 Vienna

Year: 2020
Authors:

G. Noguier1, C. Montaillier1, S. Daviere2, L. Colombeau1, E. Parussini1

1Theradiag, Research and Development, Croissy-Beaubourg, France, 2Theradiag, Theranostics, Croissy-Beaubourg, France

P694 Validation of two commercial assays for therapeutic drug monitoring of adalimumab biosimilars

ECCO'20 Vienna

Year: 2020
Authors:

R. Berghmans1, J. Naudts2, B. Ferkinghoff3, H. Gören3, M.L. Henke3, A. Lennerz4, T. Van Stappen4

1apDia bvba, Research & Development, Turnhout, Belgium, 2apDia bvba, Marketing, Turnhout, Belgium, 3R-Biopharm AG, QM/RA Technical Validation, Darmstadt, Germany, 4R-Biopharm AG, Gastroenterology, Darmstadt, Germany

P695 Vedolizumab induction and maintenance though levels and long-term clinical and biochemical status in inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

A. Gutiérrez Casbas1, L. Sempere Robles2, R. Muñoz Pérez2, A. Rodríguez Angulo2, S. Climent3, J.I. Cameo Lorenzo2, M. Díaz3, P. Boada3, P. Más-Serrano3

1Department of Gastroenterology- CIBERehd, Hospital General Universitario Alicante, Alicante, Spain, 2Department of Gastroenterology, Hospital General Universitario Alicante, Alicante, Spain, 3Department of Pharmacy, Hospital General Universitario Alicante, Alicante, Spain

P696 The usefulness to treatment enhancement for the patients of ulcerative colitis with clinical remission diagnosed as Mayo endoscopic subscore 1

ECCO'20 Vienna

Year: 2020
Authors:

M. Kubota Kajiwara, K. Uchiyama, Y. Azuma, R. Yasuda, S. Takayama, T. Takagi, Y. Naitoh

Kyoto Prefectural University of Medicine, Gastroenterology and Hepatology, Kyoto, Japan

P697 Efficacy and safety of ustekinumab in Crohn’s disease: A real-world study from Australia

ECCO'20 Vienna

Year: 2020
Authors:

P. Kakkadasam Ramaswamy, H. Moattar, E. Sawyer, J. Edwards, D. Shukla

Department of Gastroenterology, Gold Coast University Hospital, Southport, Australia

P698 IBD patients equally tolerate bowel preparation but need higher doses of sedation during colonoscopy in comparison with a population screening programme: Results from a prospective, single-centre study

ECCO'20 Vienna

Year: 2020
Authors:

C. Bezzio1, P. Andreozzi2, M. Schettino1, I. Arena1, C. Della Corte1, M. Devani1, G. Manes1, B. Omazzi1, S. Saibeni1

1Gastroenterology Unit, ASST Rhodense - Ospedale di Rho, Rho, Italy, 2Gastroenterology Unit, Marcianise Hospital, Marcianise, Italy

P699 The concordance of Short Form-36 Health Survey scores with Mayo scores in the tofacitinib ulcerative colitis clinical programme

ECCO'20 Vienna

Year: 2020
Authors:

M.C. Dubinsky1, A.G. Bushmakin2, J.C. Cappelleri2, J. Woolcott3, P. Sharma4, E. Maller3, L. Salese3, A. Armuzzi5

1Icahn School of Medicine at Mount Sinai, New York, New York, USA, 2Pfizer Inc., Groton, Connecticut, USA, 3Pfizer Inc., Collegeville, Pennsylvania, USA, 4Pfizer Inc., New York, New York, USA, 5IBD Unit- Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy

P700 Effect of vitamin D in disease activity score and clinical relapse in patients with inflammatory bowel disease: A systematic review and meta-analysis

ECCO'20 Vienna

Year: 2020
Authors:

Y. Guzman1, O. Samson1, J.P. Segal2, J.K. Limdi3, B. Hayee4

1NA, na, Bournemouth, UK, 2London North West University Healthcare, NHS Trust, London, UK, 3Pennine Acute Hospitals, NHS Trust, Oldham, UK, 4King’s College Hospital, NHS Foundation Trust, London, UK

P701 New onset spondyloarthropathy in vedolizumab treated IBD patients

ECCO'20 Vienna

Year: 2020
Authors:

A.M. Tetley1, T. Lobaton2, M. Truyens2, K.H. Katsanos3, K.H.N. de Boer4, A. Pattinson5, T. Molnar6, R. Filip7, G. Michalopoulos8, S. Sebastian5

1Gastroenterology, Hull York Medical School, Hull, UK, 2Department of Gastroenterology, Ghent University Hospital, Ghent, Belgium, 3University of Ioannina School of Health Sciences, Division of Gastroenterology, Ioannina, Greece, 4Department of Gastroenterology and Hepatology, Amsterdam UMC- VU University Medical Center, Amsterdam, Netherlands Antilles, 5IBD Unit- Department of Gastroenterology, Hull University Teaching Hospitals NHS Trust, Hull, UK, 6First Department of Medicine, University of Szeged, Szeged, Hungary, 7Department of Gastroenterology, Clinical Hospital 2- University of Rzeszow, Rzeszow, Poland, 8Gastroenterology Department, Tzaneion General Hospital of Piraeus, 8, Piraeus, Greece

P702 Treatment decisions in older inflammatory bowel disease patients: Applying gut feeling in an evidence-based era? A qualitative study

ECCO'20 Vienna

Year: 2020
Authors:

S. Waars1, V. Asscher1, A. Pieterse2, A. van der Meulen-de Jong1, S. Mooijaart3,4, J. Maljaars1

1Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands, 2Medical Decision Making- Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, The Netherlands, 3Department of Geriatrics and Gerontology, Leiden University Medical Centre, Leiden, The Netherlands, 4Institute for Evidence-Based Medicine in Old Age IEMO, Institute for Evidence-Based Medicine in Old Age IEMO, Leiden, The Netherlands